论文部分内容阅读
Background:Nonalcoholic steatohepatitis(NASH)is a common disease that is associated with increased morbidity and mortality,but treatment options are limited.The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients wi